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Abstract
Transforming growth factor-β (TGF-β) promotes cancer invasion and metastasis and is 
therefore a potential drug target for cancer treatment. Fresolimumab, a monoclonal 
antibody which neutralizes all mammalian active isoforms of TGF-β, was radiolabeled 
with zirconium-89 (89Zr) for PET imaging to analyze TGF-β expression, antibody tumor 
uptake and organ distribution. 
89Zr was conjugated to fresolimumab using the chelator N-succinyl-desferrioxamine-B-
tetrafluorphenol. 89Zr-fresolimumab was analyzed for conjugation ratio, aggregation, 
(radiochemical) purity, stability and immunoreactivity. 89Zr-fresolimumab tumor uptake 
and organ distribution was assessed using three protein doses (10, 50 and 100 µg) and 
compared with 111In-IgG in a human TGF-β transfected CHO xenograft model, a human 
breast cancer MDA-MB-231 xenograft and metastatic model. Latent and active TGF-β1 
expression was analyzed in tissue homogenates with ELISA. 
89Zr was labeled to fresolimumab with high specific activity (> 1 GBq/mg), high yield 
and high purity (> 95%). In vitro validation of 89Zr-fresolimumab showed a fully 
preserved immunoreactivity and long (> 1 week) stability in solution and in human 
serum. In vivo validation showed a 89Zr-fresolimumab distribution similar to IgG in most 
organs, except for a higher uptake in liver in all mice and higher kidney uptake in the 
10 µg group. 89Zr-fresolimumab induced no toxicity in mice. It accumulated in primary 
tumors and metastases similar to IgG. Both latent and active TGF-β were detected in 
tumor homogenates, while only latent TGF-β could be detected in liver homogenates. 
Remarkably high 89Zr-fresolimumab uptake was seen in sites of tumor ulceration and in 
scar tissue, processes in which TGF-β is known to be highly active.
Conclusion: Fresolimumab tumor uptake and organ distribution can be visualized and 
quantified with 89Zr-fresolimumab PET imaging. This technique will be used to guide 
further clinical development of fresolimumab and could possibly identify patients most 
likely to benefit. 
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The pleiotropic transforming growth factor-β (TGF-β) is excreted in low amounts by 
multiple cell types to prevent progression of premalignant lesions (1,2). In many tumor 
types the tumor suppressive responses to TGF-β are lost in the malignant phase, where 
tumor promotive responses to TGF-β (including epithelial-to-mesenchymal transition, 
angiogenesis, extravasation, migration, invasion and immune suppression) prevail. 
TGF-β thereby contributes to a more invasive and metastatic tumor phenotype (1,3). 
Mechanisms involved in this suppressor to promoter switch are diverse and include 
mutations (and epigenetic silencing) in the suppressive pathway, and increased TGF-β 
production, release and activation in the tumor microenvironment (1,4,5). Activity of 
TGF-β is locally controlled in the extracellular matrix by cleavage of active TGF-β dimers 
from the latent precursor (6,7).
TGF-β is a potential drug target for cancer treatment, especially in case of highly invasive 
or metastatic tumors such as glioblastomas and metastatic breast cancer (8,9). Strategies 
in clinical development for TGF-β inhibition include antisense oligonucleotides, TGF-β 
neutralizing antibodies and small molecule TGF-β receptor kinase inhibitors (9,10). 
Clinical TGF-β imaging can have an unprecedented role in the development of these 
TGF-β targeted agents, since the dual functions of TGF-β in cancer makes proper 
patient selection of crucial value. Selection seems especially important in breast cancer. 
Pathway analysis identified a subset of breast cancer patients with high expression of 
TGF-β pathway genes and an association with shorter distant-metastasis-free survival, 
indicating a potential benefit of TGF-β inhibition for these patients (11). In addition, 
others have identified a subset of patients with abrogated TGF-β signaling which was 
associated with reduced relapse-free survival (12). 
Improved insight into the role of TGF-β in breast cancer invasion and metastasis has 
recently been provided in a number of elegant preclinical optical imaging studies. Live 
intravital imaging of TGF-β signaling in tumor cells was performed in an orthotopic mouse 
model using rat breast cancer cells (MTLn3E) transfected with cyan fluorescent protein 
TGF-β dependent reporter constructs. Here, TGF-β signaling was transiently and locally 
activated in single moving tumor cells. TGF-β activated single moving cells demonstrated 
increased tendency to infiltrate surrounding tissues and were consequently responsible 
for distant metastases (13). TGF-β bioluminescence imaging using human breast cancer 
cells (MDA-MB-231) transfected with TGF-β responsive luciferase constructs indicated 
a temporal TGF-β dependency of bone metastases and an antimetastatic effect of 
TGF-β inhibition (14,15). These TGF-β responsive imaging approaches have provided a 
great extension of our understanding of TGF-β signaling in metastasis, but regretfully 
are restricted to preclinical use because of the use of transfections and the poor tissue 
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penetration of optical techniques. Clinically applicable TGF-β imaging techniques would 
therefore be of value in our clinical understanding of TGF-β, in the development of TGF-β 
targeting agents and in the selection of patients most likely to benefit.
Fresolimumab is a fully human IgG4 kappa monoclonal antibody capable of neutralizing 
all mammalian active isoforms of active TGF-β (1, 2, and 3). A phase I study with 
fresolimumab in 22 patients with advanced melanoma and renal cell carcinoma showed 
stable disease in one patient, a partial response in one patient and mixed tumor response 
in three patients, and no dose limiting toxicity (16). For further clinical development 
of fresolimumab and to identify the patients most likely to benefit, it will be helpful 
to know whether TGF-β is being overexpressed and activated in the tumor, and if 
fresolimumab reaches the target. Labeling fresolimumab with the long-lived positron 
emitter zirconium-89 (89Zr) should allow for non-invasive monitoring and quantification 
of fresolimumab tumor and organ distribution using positron emission tomography (PET). 
Preclinical studies, as well as, ongoing clinical studies with 89Zr-bevacizumab for imaging 
vascular endothelial growth factor (VEGF), previously demonstrated the feasibility of 
PET imaging with antibodies against soluble ligands overexpressed in tumors (17,18). 
In this study, we describe the development, quality control and preclinical validation of 
89Zr-fresolimumab for non-invasive PET imaging of TGF-β tumor expression and organ 
distribution of fresolimumab. We used two human TGF-β transfected CHO xenograft 
models, one with intermediate and one with high TGF-β expression. In addition, we 
used a MDA-MB-231 xenograft and metastatic model of human breast cancer. The triple 
negative breast cancer cell line MDA-MB-231 was selected because of the considered 
role of TGF-β in triple negative breast cancer and the extensive data available concerning 
the role of TGF-β in this cell line (14,15).
Materials and methods
Cell cultures
Chinese Hamster Ovary (CHO) clones were generated by transfection of DG44-CHO 
cells with human latent TGF-β1 (generously provided by Genzyme). Briefly, DG44-CHO 
cells were transfected with a human latent TGF-β1 cDNA using the SV2DHFR vector, 
and stable cell lines were generated by methotrexate selection. CHO Clone11S (CHO-
Cl11S) and Clone2 (CHO-Cl2) were selected as they produced intermediate (23.3 ng per 
1x106 cells per day) and high (189 ng per 1x106 cells per day) levels of human latent 
TGF-β1, respectively. CHO-Cl11S and CHO-Cl2 were cultured in a humidified incubator at 
5% CO2 and 37 0C in MEM, supplemented with 10% dialyzed fetal calf serum (FCS) and 
2% L-glutamine. The triple negative breast cancer cell-line MDA-MB-231 (from ATCC), 
and its luciferase transfected bone-tropic clone MDA-MB-231-SCP2luc (provided by Y. 
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Kang and described earlier (19)), were cultured in a humidified incubator at 5% CO2 and 
37 0C in D-MEM, supplemented with 10% FCS and 1% L-glutamine. Concentrations of 
active and total TGF-β1 in culture media were assessed using an enzyme-linked immuno 
sorbent assay (ELISA; R&D Systems) according to the manufacturers’ protocol. 
Conjugation, 89Zr-labeling and quality control of fresolimumab 
Fresolimumab (GC1008; provided by Genzyme) conjugation and labeling was performed 
as described by Verel et al (20). Briefly, fresolimumab was first conjugated with the chelator 
N-succinyldesferrioxamine-B-tetrafluorphenol (N-sucDf-TFP; generously provided by 
prof.dr. GAMS van Dongen from VUMC) in 5-fold molar excess. After conjugation, the 
product was purified by ultracentrifugation using a 30 kDa Vivaspin-2 (Sartorius) and 
stored in water for injection at -20 0C. In the second step, N-sucDf-fresolimumab was 
freshly radiolabeled with clinical-grade 89Zr oxalate (IBA Molecular) on the day of use. 
N-sucDf-fresolimumab and 89Zr-fresolimumab were analyzed for conjugation ratios, 
aggregation and (radiochemical) purity by size exclusion high performance liquid 
chromatography (SE-HPLC). The Waters SE-HPLC system was equipped with a dual-
wavelength absorbance detector, an in-line radioactivity detector and a size exclusion 
column (Superdex 200 10/300 GL; GE Healthcare). Sodium phosphate buffer (0.025 
M Na2HPO4·2H2O / NaH2PO4·H2O) was used as mobile phase. The retention time of 
fresolimumab was approximately 18 min, 89Zr-N-SucDf and low-weight impurities eluted 
at 28 min (at a flow of 0.7 mL/min). 
Stability of 89Zr-fresolimumab was tested in 0.9% NaCl at 4 0C and in human serum at 
37 0C using 20% trichloroacetic acid (TCA; Hospital Pharmacy, UMCG) precipitation. 
TCA precipitation was carried out in phosphate-buffered saline (PBS; 140 mM NaCl, 
9 mM Na2HPO4, 1.3 mM NaH2PO4; pH = 7.4) with 0.5% human serum albumin (HSA; 
Sanquin) and 20% TCA. Radioactivity in precipitate and supernatant was determined by 
a calibrated well-type gamma-counter (LKB Wallac).
Immunoreactivity was tested in a competition assay with unlabeled fresolimumab. 
Recombinant human TGF-β3 (Peprotech) was used as target antigen because 
fresolimumab has the highest affinity (with a dissociation constant of 1.4 nM) for 
this TGF-β isoform and therefore binding to TGF-β3 serves as a sensitive indicator for 
immunoreactivity of 89Zr-fresolimumab. TGF-β3 was diluted in PBS to a concentration 
of 4 µg/mL (pH was adjusted to 9.2–9.5 with 50 mmol/L Na2CO3) and coated to Nunc-
Immuno BreakApart ELISA plates (NUNC). Fifty µL was added to the wells, incubated 
overnight at 4 0C, and then blocked with 1% HSA in PBS. After blocking, plates were 
washed with 0.1% polysorbate 80 (Sigma-Aldrich) in PBS. 89Zr-fresolimumab and 
fresolimumab were mixed and diluted in PBS to result in a fixed concentration of 14 nM 
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89Zr-fresolimumab and varying concentrations of unlabeled fresolimumab, ranging 14 
pM tot 14 μM. These samples were added to the wells, and incubated for 2 h. Samples 
were collected in 2 wash steps. Both 89Zr-fresolimumab bound to the TGF-β3-coated wells 
and the collected samples containing unbound 89Zr-fresolimumab were measured for 
radioactivity. Percentage of TGF-β3 binding was calculated as the fraction of radioactivity 
bound to TGF-β3-coated wells divided by the total amount of radioactivity added. These 
percentages were plotted using Prism software (GraphPad), and the concentration that 
results in 50% inhibition of the maximum binding (IC50) was calculated.
Conjugation and 111In-labeling of control human IgG
Human IgG (Sanquin) conjugation and labeling were performed according to Ruegg 
et al (21). Briefly, IgG was first conjugated to the bifunctional conjugating agent 
2-(4-Isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid (p-SCN-Bn-DTPA; 
Macrocyclics). After conjugation, the product was purified by ultracentrifugation using 
a 30 kDa Vivaspin-2 and stored at -20 °C. Conjugated human IgG was radiolabeled with 
111InCl3 (Covidien) on the day of use. 
Animal studies 
In vivo imaging and biodistribution experiments were conducted using male athymic 
mice (BALB/cOlaHsd nude; Harlan). All experiments were approved by the animal ethics 
committee of the University of Groningen. Tumor cell inoculation and imaging was 
performed with isofluran inhalation anesthesia (induction 3%, maintenance 1.5%).
For the CHO xenograft model, mice were injected subcutaneously with 2 x 106 CHO-
Cl2 or CHO-Cl11S cells suspended in Hank's Buffered Salt Solution (HBSS; Invitrogen). 
89Zr-fresolimumab (5 MBq; 10, 50 or 100 µg) and 111In-IgG (3 MBq; 10, 50 or 100 µg) 
were administered via the penile vein. For the MDA-MB-231 xenograft model, mice were 
injected subcutaneously with 2 x 106 MDA-MB-231 cells mixed equally with Matrigel™ 
(BD Bioscience). 89Zr-fresolimumab (5 MBq; 10 µg) and 111In-IgG (3 MBq; 10 µg) were 
administered via the penile vein. For the MDA-MB-231 metastatic model, mice were 
injected intracardially (left ventricle) with 105 MDA-MB-231-SCP2luc cells suspended 
in PBS. Metastatic tumor growth was measured twice weekly with bioluminescence 
imaging (BLI). BLI was performed for 30-45 min after intraperitoneal administration of 
150 mg/kg D-luciferin with an IVIS100 (Xenogen). When metastatic tumor growth was 
measurable, approximately 2-4 weeks after inoculation, 89Zr-fresolimumab (5 MBq; 10 
µg) and 111In-IgG (3 MBq; 10 µg) were administered via the penile vein. 
All animals were imaged using a microPET Focus 220 rodent scanner (CTI Siemens) and 
subsequent microCT imaging using a MicroCAT II (CTI Siemens). Static images of 15-
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45 min acquisition time were obtained at 24, 72 and 144 h postinjection. After image 
reconstruction, in vivo quantification was performed with AMIDE Medical Image Data 
Examiner software (version 0.9.1, Stanford University) and tumor accumulation was 
calculated as Standardized Uptake Value (SUV) (22). Animals were sacrificed after the 
last scan and organs were excised, rinsed for residual blood, weighed and counted 
for radioactivity. Tissue activity was expressed as percentage injected dose per gram 
tissue (%ID/g). Subsequently, organs of interest were split and partly formalin fixed and 
paraffin embedded for histological analysis and partly stored at -80 0C for ex vivo TGF-β1 
measurement.
Ex vivo analyses on organ of interest tissue
Ex vivo TGF-β1 measurement was performed in organs of interest using an enzyme-
linked immuno sorbent assay (ELISA; R&D Systems) according to the manufacturers’ 
protocol. This ELISA measures active TGF-β1 quantitatively and latent TGF-β1 was 
measured after activation by acidification to discriminate between latent and active 
TGF-β1. Measurement of TGF-β1 was performed because CHO cells were transfected 
with this isoform. Formalin-fixed, paraffin-embedded organs of interest were stained 
with hematoxylin and eosin (H&E) and for phospho-Smad2 (Cell Signaling). Staining for 
phospho-Smad2 (pSmad2) served as a surrogate for active TGF-β, since it is currently not 
possible to stain for active TGF-β itself. 
Statistical analysis
Data are presented as mean ± standard deviation (SD) from at least three individual 
experiments/animals, unless stated otherwise. Statistical analysis was performed using 
the Mann-Whitney test for non-parametric data and the unpaired T-test for parametric 
data. A P value ≤ 0.05 was considered significant.
Results
89Zr-fresolimumab labeling and quality control
HPLC analysis showed an aggregation of 1.4 ± 1.1% after conjugation of fresolimumab 
with sucDf-TFP and an effective conjugation of 62 ± 9%. N-sucDf-fresolimumab could 
be labeled with 89Zr to a specific activity of up to 1000 MBq/mg with a radiochemical 
purity of 97.0 ± 1.2% over all experiments, not requiring further purification. A typical 
representative HPLC analysis of 89Zr-fresolimumab is shown in Fig. 1A.
89Zr-fresolimumab was highly stable in solution (0.9% NaCl) at 4 0C and in human serum 
at 37 0C over > 168 h. Average decrease in radiochemical purity of 89Zr-fresolimumab per 
day in human serum at 37 0C was 0.44 ± 0.13, 0.84 ± 0.11 and 1.21 ± 0.09% for a specific 
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activity of 250, 500 and 1000 MBq, respectively. Average decrease in radiochemical 
purity of 89Zr-fresolimumab per day in solution (0.9% NaCl) at 4 0C was 0.42 ± 0.05%.
To proof that labeling fresolimumab did not alter the activity of fresolimumab, a 
competitive binding experiment was performed with unlabeled fresolimumab in 
competition with 89Zr-fresolimumab. This resulted in an average IC50 of 18 nM 
fresolimumab (95% confidence interval of 12-28 nM) for the competition of TGF-β3 
binding of 14 nM 89Zr-fresolimumab, indicating fully preserved immunoreactivity (Fig. 
1B).
Fig. 1
Quality control of 89Zr-fresolimumab. Panel A shows a typical HPLC of 89Zr-fresolimumab with detection at 
280 nm for the protein signal and co-registration of radioactive signal. Immunoreactivity of 89Zr-fresolimumab 
was determined in a competitive binding assay with unlabeled fresolimumab. Competition curve (with 95% 
confidence interval) for the binding of 89Zr-fresolimumab to TGF-β3 is shown in B.
FIGURE 1





















































































89Zr-fresolimumab μPET imaging and biodistribution in CHO xenografts
89Zr-fresolimumab μPET imaging was first performed on mice harboring xenograft 
tumors with CHO clones expressing intermediate and high levels of human latent 
TGF-β1. Assessment of in vitro expression of human latent TGF-β1 in culture media 
samples with ELISA confirmed the intermediate and high expression of CHO-Cl11S 
and CHO-Cl2, respectively (data not shown). μPET imaging of mice bearing CHO-Cl11S 
and CHO-Cl2 tumors with 89Zr-fresolimumab indicated clear tumor accumulation and 
visualization in both models at 72 and 144 h postinjection, with a slightly higher tumor 
uptake at 144 h postinjection (Fig. 2A and 2C). No visual difference in 89Zr-fresolimumab 
tumor uptake between both CHO clones could be detected and also quantification of 
the tumor uptake as assessed by SUV did not show a difference: SUV in CHO-Cl2 was 
A B
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2.0 ± 0.1 and 2.3 ± 0.2 at 72 and 144 h postinjection, respectively, and SUV in CHO-Cl11S 
was 2.0 ± 0.4 and 2.2 ± 0.6 at 72 and 144 h postinjection, respectively. Ex vivo analysis of 
89Zr-fresolimumab and 111In-IgG biodistribution indicated similar uptake of both tracers 
in all tumors and comparable distribution over most organs (Fig. 2B and 2D). Organ 
uptake of 89Zr-fresolimumab was higher than 111In-IgG in liver and bone of both groups 
of mice. Subgroup analysis of the different protein doses of 89Zr-fresolimumab showed 
similar tumor uptake of 10, 50 or 100 µg 89Zr-fresolimumab, with a non-significant trend 
towards lower liver uptake in the 10 µg dose group (Table 1). Only in the 10 µg group 
there was a 92 ± 28% higher uptake of 89Zr-fresolimumab than 111In-IgG in kidneys (P 





































































































































μPET imaging with 89Zr-fresolimumab showed tumor uptake in both CHO-Cl11S and CHO-Cl2 (A and C; arrow 
indicates tumor). Tumor uptake and organ distribution of 89Zr-fresolimumab and control 111In-IgG as was 
quantified ex vivo (B and D).
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111In-IgG in all individual mice with a mean difference of 69 ± 28% (P = 0.0005; Fig. 3A). To 
assess whether this was caused by high TGF-β levels in the liver, we determined TGF-β1 
levels in liver homogenates with ELISA. Levels of active TGF-β1 were below the detection 
limit in all samples and levels of latent TGF-β1 were 0.22 ± 0.16 and 0.10 ± 0.07 ng/
mg protein in livers of mice with CHO-Cl2 and CHO-Cl11S xenografts, respectively (Fig. 
3B). TGF-β1 levels in tumor homogenates also showed the same pattern of higher levels 
in tissue from CHO-Cl2 xenografts compared to CHO-Cl11S xenografts, although not 
significant (Fig. 3C). The highest TGF-β1 levels were found in homogenates of tumors 
in two mice with skin ulceration at the tumor site. These tumors showed a focally 
increased 89Zr-fresolimumab uptake at the site of ulceration with μPET imaging (Fig. 3D). 
This correlated with TGF-β1 levels in homogenates of the ulcerations of 26 and 21 ng 
latent TGF-β1/mg protein, which were the highest levels of all tissue samples measured 
(highest latent TGF-β1 level in tumors without ulcerations was 17 ng/mg). High 89Zr-
fresolimumab uptake was also present in sites with scar tissue in two mice that were 
victimized by their dominant congener cage mate prior to 89Zr-fresolimumab injection 
(data not shown). 
Table 1: Dose escalation of 89Zr-fresolimumab and control 111In-IgG.
Data are expressed as percentage of injected dose per gram tissue (mean ± SD). * 89Zr-fresolimumab is 
abbreviated as 89Zr-fres.
10 µg (n=5) 50 µg (n=2) 100 µg (n=6)
89Zr-fres. 111ln-lgG 89Zr-fres. 111ln-lgG 89Zr-fres. 111ln-lgG
Heart 3.47 ± 0.59 3.61 ± 0.57 3.53 ± 0.54 3.88 ± 0.63 4.58 ± 0.66 3.72 ± 0.37
Blood 8.23 ± 1.47 10.71 ± 1.93 9.03 ± 2.32 12.29 ± 2.40 7.79 ± 1.84 10.07 ± 1.50
Lung 7.76 ± 3.98 7.27 ± 2.10 4.99 ± 1.31 5.55 ± 1.14 4.46 ± 1.12 4.72 ± 1.05 
Liver 6.31 ± 1.71 4.27 ± 0.96 6.69 ± 1.12 3.49 ± 0.09 8.91 ± 2.21 4.93 ± 1.00
Kidney 8.10 ± 0.75 4.32 ± 0.80 4.37 ± 0.18 3.45 ± 0.40 4.08 ± 0.38 3.79 ± 0.54
Urine 1.91 ± 1.55 1.82 ± 1.16 0.68 ± 0.05 0.94 ± 0.09 1.01 ± 0.41 1.65 ± 0.87
Bladder 4.23 ± 1.15 4.83 ± 0.90 3.16 ± 0.64 3.80 ± 0.71 3.29 ± 0.83 3.39 ± 0.89
Stomach 1.40 ± 0.28 1.47 ± 0.32 1.17 ± 0.05 1.18 ± 0.03 1.39 ± 0.16 1.39 ± 0.12
Pancreas 0.96 ± 0.52 1.08 ± 0.57 1.37 ± 0.36 1.54 ± 0.31 1.14 ± 0.20 1.29 ± 0.19
Spleen 5.22 ± 0.65 5.02 ± 0.71 5.43 ± 0.87 4.88 ± 1.02 5.83 ± 0.39 4.93 ± 0.47
Small intestine 1.38 ± 0.52 1.58 ± 0.71 1.38 ± 0.30 1.57 ± 0.31 1.55 ± 0.66 1.73 ± 0.66
Large intestine 1.48 ± 0.35 1.84 ± 0.58 1.39 ± 0.08 1.63 ± 0.05 1.17 ± 0.21 1.33 ± 0.26
Muscle 1.14 ± 0.40 1.34 ± 0.31 0.98 ± 0.04 1.27 ± 0.05 1.18 ± 0.14 1.31 ± 0.18
Bone 4.05 ± 0.77 2.04 ± 0.39 3.50 ± 0.42 1.75 ± 0.48 2.28 ± 0.81 1.50 ± 0.53
Tumor 5.64 ± 1.80 6.22 ± 2.17 5.99 ± 0.24 7.05 ± 0.71 6.56 ± 1.75 6.76 ± 1.58
Brain 0.23 ± 0.08 0.30 ± 0.10 0.21 ± 0.04 0.26 ± 0.04 0.25 ± 0.09 0.32 ± 0.10
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Liver uptake of 89Zr-fresolimumab and 111In-IgG in CHO xenograft mice (A). TGF-β1 levels were determined 
by ELISA in homogenates of liver (B) and tumor (C) tissue. Two mice with a skin ulceration at the tumor site 



























































Histological and immunohistochemical staining for hematoxylin and eosin (H&E) and phospho-Smad2 
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μPET imaging (A) and ex vivo biodistribution at 144 h postinjection (B) of 89Zr-fresolimumab in MDA-MB-231 
xenografts.
Histological analysis of CHO xenograft tumors and livers
H&E staining showed no obvious difference in morphology between tumors from 
xenografts of either of the CHO clones (Fig 4). All tumors largely consisted of vital 
vascularized tissue with tumor and stromal cells, and minor areas of necrosis. H&E 
staining of livers from CHO xenograft mice showed a normal morphology. All tested 
samples showed nuclear staining for pSmad2. Concurring with the μPET data, there was 
no difference in pSmad2 staining in tumors and livers from xenograft mice of both CHO 
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89Zr-fresolimumab μPET imaging and biodistribution in MDA-MB-231 xenografts
To further investigate the organ and tumor distribution of 89Zr-fresolimumab we used 
the MDA-MB-231 human breast cancer xenograft model. μPET imaging showed a clear 
89Zr-fresolimumab tumor accumulation over time (Fig. 5A). Tumor accumulation was 
also shown by SUV quantification: 1.5 ± 0.2, 2.3 ± 0.3 and 2.6 ± 0.3 at 24, 72 and 144 h 
postinjection, respectively. Ex vivo biodistribution analysis again showed a similar tumor 
uptake of non-specific control 111In-IgG at 144 h postinjection (Fig. 5B). Organ uptake of 
89Zr-fresolimumab was higher than 111In-IgG in liver (P = 0.0459), kidneys (P = 0.0078) and 
bone (P = 0.0007) and reflected the biodistribution seen in CHO xenografts.
89Zr-fresolimumab μPET imaging and biodistribution in MDA-MB-231-SCP2luc 
metastatic model
Because TGF-β is involved in breast cancer metastasis (13,14), we evaluated 89Zr-
fresolimumab imaging in a metastatic breast cancer model as well. All mice had developed 
multiple (bone) metastases 3-5 weeks after intracardiac injection of MDA-MB-231-
SCP2luc cells, as was visualized with bioluminescence imaging (Fig. 6), corresponding 
BLI PET PET/CT
Fig. 6
Representative example of bioluminescence (BLI) and μPET/ CT images of a mouse in which bone metastatic 
MDA-MB-231-SCP2-luc cells were injected into the left ventricle of the heart in a disseminated model of 




B I PET PE /CT
Proefschrift.indb   77 01-03-15   14:47
Chapter 4 | PET imaging with 89Zr labeled TGF-β antibody fresolimumab
78
with results from others with this model (19). Metastases were mainly localized in jaws, 
skull, sternum, spine, shoulders, hips and lower limbs. Both µCT and 89Zr-fresolimumab 
µPET imaging did not visualize any of the metastases detected by bioluminescence 
imaging. Only one mouse showed 89Zr-fresolimumab uptake at a site suspicious for 
metastasis (Fig. 6). Ex vivo 89Zr-fresolimumab biodistribution was similar as was found 
in CHO and MDA-MB-231 xenograft models with high liver uptake of 89Zr-fresolimumab 
(data not shown). No toxicity of 89Zr-fresolimumab was seen in any of these mice.
Discussion
In the present study, we describe for the first time the development, quality control and 
preclinical validation of 89Zr-fresolimumab for non-invasive PET imaging of tumor and 
organ distribution of fresolimumab. 
Development and quality control of 89Zr-fresolimumab provided similar results as we 
had seen earlier with the 89Zr labeling of antibodies directed at other targets (17,23), 
indicating the robustness of this labeling method. μPET imaging with 89Zr-fresolimumab 
showed tumor uptake in CHO xenografts and in MDA-MD-231 xenografts. Remarkably 
high 89Zr-fresolimumab uptake was seen in sites of tumor ulceration in two mice and in 
scar tissue of two other mice, processes in which TGF-β is involved (24).
Our study showed for 89Zr-fresolimumab a distribution comparable to 111In-IgG in most 
organs, except for a higher uptake in liver and kidneys. This increased uptake in non-
tumor organs was not seen previously with vascular endothelial growth factor (VEGF) 
directed 89Zr-bevacizumab and human epidermal growth factor receptor-2 (HER2) 
directed 89Zr-trastuzumab (17,23). 89Zr-fresolimumab liver uptake was especially 
increased when higher fresolimumab doses were used. The higher 89Zr-fresolimumab 
kidney uptake was only seen in the low dose 89Zr-fresolimumab group of 10 μg. High liver 
uptake of 89Zr-fresolimumab likely is the result of a specific, TGF-β driven, interaction 
between 89Zr-fresolimumab and TGF-β in the liver and would thus indicate high levels 
of active TGF-β in the liver. Our analysis of liver homogenates did not show high levels 
of the active TGF-β1 form. However, immunohistochemical staining for pSmad2 of liver 
tissues indicated that active TGF-β was present in the liver within hours before tissue 
collection (25). This presence of active TGF-β has probably caused the accumulation of 
89Zr-fresolimumab in the liver and can be the consequence of rapid hepatic clearance 
of active TGF-β from the circulation and subsequent lysosomal degradation (26). This 
might mean that human TGF-β from CHO or MDA-MD-231 tumors will upon activation 
be rapidly cleared by the liver, where it accumulates, is recognized by 89Zr-fresolimumab, 
and results in 89Zr-fresolimumab accumulation in the liver. In addition to tumor derived 
human TGF-β, activated mouse TGF-β from non-tumor origin likely will accumulate 
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in the liver and result in high 89Zr-fresolimumab liver uptake, since fresolimumab also 
binds to mouse TGF-β with high affinity. Another reason for the high liver uptake might 
be complex formation of 89Zr-fresolimumab with active TGF-β in the tumor micro-
environment and in the circulation, subsequently followed by hepatic clearance of this 
complex. All together, this indicates a TGF-β specific biodistribution of 89Zr-fresolimumab. 
Additionally, the high 89Zr-fresolimumab liver uptake also matches strikingly the available 
preclinical data on the biodistribution of 111In-decorin. Decorin, a small proteoglycan 
from the extracellular matrix, binds TGF-β with high affinity. Intravenous injection of 
111In-decorin into mice showed rapid hepatic clearance, especially by accumulation in 
nonparenchymal cells (27). The high liver uptake of 89Zr-fresolimumab reported in this 
preclinical study indicates the relevance of clinical 89Zr-fresolimumab imaging studies to 
explore not only fresolimumab tumor uptake but also its organ distribution. Increased 
kidney uptake of 89Zr-fresolimumab likely is not the representation of 89Zr-fresolimumab 
uptake caused by high TGF-β kidney levels, but uptake of 89Zr-fresolimumab catabolites 
from hepatic processing. Hepatic processing is often saturable and thus dose-dependent, 
thereby explaining that increased kidney uptake of 89Zr-fresolimumab catabolites was 
only seen in the lowest 89Zr-fresolimumab dose of 10 μg. The high bone uptake of 89Zr-
fresolimumab, compared to 111In-IgG, can be the result of high TGF-β levels in bone (28). 
However, we cannot exclude that this is an artefact due to bone uptake of dissociated 
89Zr since we have also seen higher bone uptake of 89Zr-bevacizumab when compared 
with 111In-bevacizumab (17). 
To study specificity of 89Zr-fresolimumab, tumor uptake results were compared with 
111In-IgG. This showed that tumor uptake of 89Zr-fresolimumab was similar to 111In-IgG 
tumor uptake. Lack of specific, i.e. TGF-β driven, tumor uptake of 89Zr-fresolimumab in 
our models could be a consequence of the fact that fresolimumab binds selectively to 
the active form of TGF-β. Our ELISA analysis of TGF-β1 levels in tumor homogenates, as 
well as clinical ELISA data on tumor homogenates of gastric cancer patients (29), show 
that more than 90% of total TGF-β is present in its latent form, leaving little antigen for 
fresolimumab binding. Our CHO models were generated to produce latent TGF-β1, since 
this would be more resembling natural conditions than cells that produce active TGF-β1 
because all normal and tumor cells only produce TGF-β in its latent form. However, 
specific accumulation of 89Zr-fresolimumab requires local activation of TGF-β1 in the 
tumor, and not all TGF-β activating mechanisms necessarily result in the release of free 
active TGF-β (30). Additional to the low levels of free active TGF-β, also the biological half-
life of active TGF-β is with 2-3 min much shorter than that of latent TGF-β (110 min) (31), 
making imaging of TGF-β with an antibody recognizing only the active form even more 
challenging. Obviously, this does not exclude the therapeutic potential of fresolimumab. 
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Our imaging data clearly show tumor accumulation of fresolimumab, likely because 
of the enhanced permeability and retention effect (32), indicating that fresolimumab 
reaches the target site in high concentrations (6.1 ± 1.6 % of injected dose per gram 
tumor over all mice). Presence of fresolimumab in the tumor microenvironment inhibits 
local activation of latent TGF-β, thereby reducing the stimulatory response of the tumor. 
Therefore, the amount of fresolimumab in the tumor, as visualized and quantified with 
89Zr-fresolimumab PET, could be a predictor for outcome. 
With respect to absence of specific preferential tumor uptake of 89Zr-fresolimumab, 
this tracer differed from other targeted antibody based tracers we developed. During 
imaging of other soluble tumor targets, such as VEGF, we found a 2-fold higher uptake of 
89Zr-bevacizumab in SKOV-3 xenografts versus control IgG.17 With 89Zr-trastuzumab HER2 
imaging in the same model, tumor uptake of 89Zr-trastuzumab was 5-fold higher than 
control IgG (33). However we also now know that preclinical results can underestimate 
clinical findings, since with clinical imaging studies, we found with 89Zr-bevacizumab 
a higher tumor uptake than with 89Zr-trastuzumab (18,34). These superior differential 
results in the clinical setting may prove to be the case for 89Zr-fresolimumab as well. This 
therefore supports further pursuing of TGF-β specific clinical imaging. Furthermore, the 
lack of 89Zr-fresolimumab visualization of metastases in our model of breast cancer bone 
metastases is likely caused by the sub-resolution size (< 2 mm) for μPET imaging of these 
lesions. This further illustrates the potentials of clinical evaluation of 89Zr-fresolimumab 
for a complete understanding of fresolimumab distribution in cancer patients, and to 
address the value of fresolimumab in the treatment of (metastatic) cancer. The clear 
visualization of tumor ulcerations with 89Zr-fresolimumab, together with the high 
levels of TGF-β1 we measured with ELISA in these ulcerations, encourages the further 
investigation of the use of fresolimumab in inflammatory diseases like pulmonary 
fibrosis.
In summary, 89Zr-fresolimumab µPET was shown to be preclinically feasible for 
imaging and quantification of fresolimumab tumor uptake and organ distribution. 89Zr-
fresolimumab PET is ready for clinical evaluation and might contribute to the clinical 
development of fresolimumab. We will use this technique to quantify the tumor uptake 
of fresolimumab in patients with high grade gliomas.
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